Skip to main content

Table 2 Patient’s demographics and clinical characteristics

From: The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients

Gender Females, N = 17 (38.6%)
Males, N = 27 (61.4%)
Age Range 8.10–47.17 years
Mean = 17.17 years
Grade High grade, N = 34 (77.3%)
Missing data, N = 10 (22.7%)
Histological subtypes Conventional, N = 34 (89.5%)
Variant, N = 4 (10.5%)
Missed data, N = 6
Metastasis at diagnosis Yes, N = 11 (25%)
No, N = 33 (75%)
Neoadjuvant chemotherapy MAP, N = 30 (68.2%)
Cisplatin & Doxorubicin, N = 11 (25.0%)
Other, N = 3 (6.80%)
Tumor location Arm, N = 3 (6.8%)
Femur, N = 22 (50%)
Tibia, N = 15 (34.1%)
Other, N = 4 (9.1%)
Response to chemotherapy Good, N = 16 (36.4%)
Poor, N = 28 (63.6%)